Compare CMRC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMRC | SLN |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | United States | United Kingdom |
| Employees | 1079 | 116 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.4M | 236.2M |
| IPO Year | N/A | N/A |
| Metric | CMRC | SLN |
|---|---|---|
| Price | $2.80 | $6.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.88 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 815.6K | 262.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.11 | N/A |
| Revenue Next Year | $4.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.41 | $4.19 |
| 52 Week High | $5.55 | $8.40 |
| Indicator | CMRC | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 41.75 |
| Support Level | $2.56 | $5.91 |
| Resistance Level | $3.13 | $7.21 |
| Average True Range (ATR) | 0.26 | 0.53 |
| MACD | -0.04 | -0.17 |
| Stochastic Oscillator | 10.39 | 14.29 |
Commerce.com Inc is engaged in offering a Software-as-a-Service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which the majority of its revenue is generated from Americas-U.S.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.